Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSurgical Innovations Regulatory News (SUN)

Share Price Information for Surgical Innovations (SUN)

Share Price is delayed by 15 minutes
Get Live Data
0.475    0.00 (0.00%)
Bid:
0.45
Ask:
0.50
Spread: 0.05 (11.111%)
Market Cap: £4.43m
SUN Live PriceLast checked at - London Stock Exchange

Intraday Surgical Innovations Share Chart

AGM Statement

24 Jun 2014 07:00

RNS Number : 3265K
Surgical Innovations Group PLC
24 June 2014
 



 

Press Release

24 June 2014

 

 

Surgical Innovations Group plc

 

("SI" or the "Group" or the "Company")

 

AGM Statement

 

Surgical Innovations Group plc (AIM:SUN), a leading creator of innovative medical technology to address unmet clinical needs in minimally invasive surgery ('MIS'), will hold its Annual General Meeting at 2.00pm today at Clayton Wood House, 6 Clayton Wood Bank, Leeds, LS16 6QZ, during which the Chairman, Doug Liversidge CBE, will make the following statement:

 

"The Board is pleased that the Company is now succeeding in capitalising on the infrastructure put in place over the past year. We are confident that our investment choices and strategic decisions will result in future growth. Working capital has been significantly enhanced following the investment from Chris Rea, as announced on 9 June 2014 which will support the development, together with promotion, of our unique clinical solution for 3mm surgery. We look forward to welcoming Chris to the Board.

 

"We continue to build upon last year's strong growth both in the UK and US. The Resposable® concept provides a cost-saving solution to the NHS which is committed to cost reduction programs in UK hospitals. During 2013, there was a 59% increase in the number of Yorkshire hospitals using SI branded products. The US remains a key market and the Company is effectively broadening sales channels in order to realise revenue and brand recognition opportunities. This is evidenced by the 75% increase in sales to the US of SI branded products driven primarily by new dealer relationships across the US.

 

"The Board is committed to improving our manufacturing capabilities to effectively satisfy the global demand for both SI branded and OEM products. The Group is satisfied that in recent months our continued investment is being realised in this area as significant improvements have been made.

 

"The product development pipeline continues to be strengthened through the focused investment in our 3mm 'Ultra MIS' technology, underpinned by our allegiances with Key Opinion Leaders in this specific surgical field. The Board is confident that the Group's future success will be achieved through the strategic introduction of our '3mm 'Ultra MIS' clinical solutions.

 

"Overall, we are pleased with the progress made and look to the future with confidence."

 

-Ends-

 

For further information please contact:

Surgical Innovations Group plc

Graham Bowland, Chief Executive Officer

Mike Thornton, Chief Financial Officer

Tel: +44 (0) 113 230 7597 www.sigroupplc.com

Nominated Advisor and Broker

Panmure Gordon

Freddy Crossley (Corporate Finance)

Maisie Atkinson (Corporate Broking)

Tel: +44 (0) 207 886 2500

www.panmure.com

Media Enquiries

Abchurch Communications

Sarah Hollins / Jamie Hooper / Stephanie Watson

surgical@abchurch-group.com

Tel: +44 (0) 207 398 7716

www.abchurch-group.com

 

 

 

Notes to Editors:

Surgical Innovations Group plc (AIM: SUN) is a highly reputable British-based medical device designer and manufacturer, focused on delivering innovative clinical solutions for surgeons that are both cost-effective and efficient. Since the Group's inception in 2002, its foundations have been rooted in the field of laparoscopic surgery. It has established itself as pioneers in this field and successfully developed a portfolio of innovative medical instrumentation for Minimally Invasive, or "Key-Hole", Surgery.

 

Surgical Innovations' industry leading products are centered on its pioneering "Resposable™" concept which utilises a combination of disposable and reusable components to deliver cost-efficient solutions to healthcare organisations which, in this time of financial austerity, constantly have to find budget saving alternatives that do not compromise treatment quality. Within the Group's SI Brand division, the portfolio of products includes port access systems, instrumentation and retraction devices. Not only do such devices supply the laparoscopic market, the technologies can also be transferred in to other areas of the body such as hip arthroscopy, cardiac and thoracic. Additionally the Company is also exploring alternative therapeutic avenues and thus generating additional revenue streams. It has also successfully taken its technology to the industrial sector, and can currently conduct keyhole surgery on jet engines.

 

The business has a compelling market position with an established international footprint. Through its developed network of distribution partners, Surgical Innovations' branded products are being sold in all the major high growth medical device markets, including: UK, US, South East Asia, Australasia and the Indian subcontinent. With an investment strategy focused on Sales and Marketing, the Group is well positioned and has the management expertise in place to capitalise on the growing demand, gain market share and deliver return to shareholders.

 

For more information, please see www.sigroupplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMSEEFUDFLSELM
Date   Source Headline
27th Jun 20223:15 pmRNSResult of AGM
27th Jun 20227:00 amRNSAGM Trading Statement
25th May 20227:00 amRNSPosting of 2021 Annual Report & Accounts
9th May 202212:41 pmRNSDirector/PDMR Shareholding
23rd Mar 20227:00 amRNSFinal Results
21st Mar 20227:00 amRNSProduct launch in partnership with CMR Surgical
10th Mar 20227:00 amRNSNotice of Annual Results
17th Jan 20227:00 amRNSYear-end Trading Update
15th Nov 20217:00 amRNSChanges to Board Structure & CFO Appointment
10th Nov 20215:43 pmRNSGrant of Options
15th Sep 20217:00 amRNSHalf-year Report
27th Aug 20217:00 amRNSNotice of Interim Results
9th Jul 20212:29 pmRNSDirector/PDMR Shareholding
22nd Jun 20215:26 pmRNSResult of AGM
22nd Jun 20217:00 amRNSAGM Trading Statement
21st Jun 20217:00 amRNSWithdrawal of AGM Resolution
21st May 20217:00 amRNSPosting of Annual Report& Accounts & Notice of AGM
25th Mar 20217:00 amRNSFinal Results
22nd Mar 20217:00 amRNS3-year Exclusive UK distribution agreement
8th Mar 20217:00 amRNSNotice of annual results
15th Feb 20217:00 amRNS5-year USA distribution agreement
9th Feb 20217:00 amRNSLaunch of the Green Surgery Challenge
8th Jan 20217:00 amRNSDistalmotion’s Dexter Robot receives CE Mark
7th Jan 20217:00 amRNSFuture board change
21st Dec 20207:00 amRNSTrading update
17th Dec 20207:00 amRNSUS distribution agreement signed with Adler
7th Dec 20203:00 pmRNSReplacement of Auditor
2nd Dec 20207:00 amRNSProduct launch for Cellis Breast
25th Nov 20207:00 amRNSCentre for Sustainable Healthcare collaboration
25th Sep 202011:50 amRNSHolding(s) in Company
23rd Sep 20205:20 pmRNSHolding(s) in Company
21st Sep 20201:46 pmRNSHolding(s) in Company
18th Sep 20204:08 pmRNSResult of AGM
17th Sep 202012:54 pmRNSResult of Fundraise
17th Sep 20207:01 amRNSProposed Fundraise
8th Sep 20207:00 amRNSHalf-year Report
21st Aug 20207:00 amRNSNotice of results and Change of AGM 2020 Date
10th Aug 20205:57 pmRNSHolding(s) in Company
10th Jun 20207:00 amRNSPostponement of the Annual General Meeting 2020
4th Jun 20204:50 pmRNSDirector/PDMR Shareholding
4th Jun 20207:00 amRNSNHS Sustainability Webinar
28th May 20207:00 amRNSUpdate on trading &extension to banking facilities
31st Mar 20207:00 amRNSFinal Results
27th Mar 20203:05 pmRNSNotice of results and trading update
13th Jan 20207:00 amRNSYear-end Trading Update
11th Nov 20196:09 pmRNSDirector/PDMR Shareholding
7th Nov 20197:00 amRNSDirector/PDMR Shareholding
5th Nov 20192:56 pmRNSDirector/PDMR Shareholding
25th Oct 20193:12 pmRNSDirector/PDMR Shareholding
7th Oct 20194:12 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.